EMA Application withdrawn: Corluxin (mifepristone) — FGK Representative Service GmbH

View source ↗

Summary

EMA withdrawal of Corluxin (mifepristone) application for Cushing syndrome by FGK Representative Service GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Syndrome

Drugs mentioned

• Corluxin (mifepristone)

Snippet

Status: Application withdrawn. Therapeutic area: Cushing Syndrome. MAH: FGK Representative Service GmbH. Decision date: 24/04/2015. Orphan medicine